Holen Sie sich die Stockscreener-App
0.9821
4.65%
-0.0479
Immuron Limited Adr Aktie (IMRN) Neueste Nachrichten
Immuron (IMRN) Slips 1.83% to $1.07 as Shares Drift Toward Lower SupportMA Cross Alert - https://www.dars.gov.et/
Immuron Limited Subject to Substantial Holder Notice from The Bank of New York Mellon Corporation - Kalkine
With A$9M in cash and no borrowings, Immuron (NASDAQ: IMRN) narrowed its annual loss. - Stock Titan
Kazia Therapeutics Limited (KZIA) stock price, news, quote and history - Yahoo Finance Australia
IMRN - Finviz
symbol__ Stock Quote Price and Forecast - CNN
Immuron (NASDAQ: IMRN) Secures Exclusive U.S. Distribution Rights for PROIBS in $4.16 Billion Digestive Health Market - Kalkine Media
What Does Friday’s Move Mean for Immuron (NASDAQ:IMRN) on Nasdaq? - Kalkine Media
Stay updated with the stocks that are on the move in today's after-hours session. - ChartMill
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.51% - Investing.com
Immuron LimitedADR (IMRN) Peer Comparison – Compare with Others - Value Research
Gold Falls Over 1%; American Outdoor Brands Shares Jump After Q1 Results - Benzinga
Dow Falls Over 100 Points; US Economy Adds 162,000 Jobs In August - Benzinga
IMRN Stock Jumps As Immuron Beats Guidance And Advances Pipeline - StocksToTrade
IMRN Stock Jumps As Immuron Beats Guidance And Advances Pipeline - StocksToTrade
IMRN Stock Pops As Immuron Beats Guidance And Advances Pipeline - StocksToTrade
$4.16B US gut health market in sight for Immuron (IMRN) with new PROIBS distribution deal - Stock Titan
Immuron (ASX:IMC; NASDAQ:IMRN) Brings European-Certified Medical Device PROIBS® To U.S. Consumers - kalkinemedia.com
Immuron Limited WarrantsADR (IMRNW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Immuron (NASDAQ: IMRN) ends FY26 with A$9.0m cash but stays in loss - Stock Titan
Immuron Reports FY26 Preliminary Results - Barchart.com
Kazia Therapeutics LimitedADR Peer Comparison – Compare with Others - Value Research
Immuron (IMRN) Levels: Moves 3.48% Up to $1.19 at the Close; Next Session: the Supplied Trading Band Runs From $1.13 to $1.25 at the CloseValue Area Low - careplusvn.com
Immuron (IMRN) lifts FY26 sales as it shifts to partner-funded drug development - Stock Titan
Immuron (IMRN) Levels: Moves 3.48% Up to $1.19 at the Close; Next Session: the Supplied Trading Band Runs From $1.13 to $1.25 at the CloseLow Vol Factor - dars.gov.et
Immuron (IMRN) Levels: Moves 3.48% Up to $1.19 at the Close; Next Session: the Supplied Trading Band Runs From $1.13 to $1.25 at the CloseThematic ETF Flow - dars.gov.et
Immuron (ASX: IMC) Pushes IMM-529 Forward with FDA Clearance and Partnering Strategy - Kalkine Media
Immuron Limited (NASDAQ: IMRN) highlights antibody platform and CEO talk at Emerging Growth Conference - Stock Titan
Immuron (IMRN) Holds Gains Above $1.10 as Micro-Cap Biotech Finds Buying InterestVolume Spike Alerts - careplusvn.com
Immuron (IMRN) Holds Gains Above $1.10 as Micro-Cap Biotech Finds Buying InterestCash Secured Put - dars.gov.et
Immuron (IMRN) Holds Gains Above $1.10 as Micro-Cap Biotech Finds Buying InterestChannel Breakout - vinanet.vn
PRU Q2 2026 Earnings: EPS Beats Estimates by 14.5% as Prudential Delivers Strong ResultsRevenue Breakdown Analysis - vinanet.vn
Immuron Limited (IMRN) Edges Higher to $1.08, Approaches Key Resistance at $1.13Trade Entry Signals - dars.gov.et
GLIBK Q1 2026 Earnings: EPS Misses Estimates by 63.89%, Coming in at $0.45 per ShareTangible Book Value - vinanet.vn
Immuron Limited (IMRN) Slips 1.8% as ADR Tests Key $1.04 SupportMutual Fund Flow - vinanet.vn
Immuron Limited (IMRN) Slips 1.8% as ADR Tests Key $1.04 SupportLinear Regression - dars.gov.et
Immuron (NASDAQ: IMRN) outlines FY26 growth, cash runway and CDI IND plans - Stock Titan
Immuron Limited Sponsored ADR Revenue Breakdown – MUN:ANWA - TradingView
Immuron Limited Sponsored ADR Revenue Breakdown – LSX:A2DTD8 - TradingView
Immuron Limited (NASDAQ: IMRN) highlights antibody platform at TechKnow Invest - Stock Titan
Immuron Limited (NASDAQ: IMRN) grows FY26 revenue to A$7.7m - Stock Titan
Immuron CEO, Steven Lydeamore presentation at Kalkine Media Webinar - Barchart.com
Immuron FY26 SalesFour Consecutive Quarters of Growth over Prior Year - Sahm
BNY Mellon Lifts Substantial Holding in Immuron to 44.61% via ADR Program Deposits - Kalkine
Immuron (NASDAQ: IMRN) lifts FY26 Travelan sales 6% to AUD$7.7m - Stock Titan
BNY Mellon Boosts Immuron Stake to 44.61% Through ADR Share Deposits by July 2026 - Kalkine Media
Immuron FY26 SalesFour Consecutive Quarters of Growth over Prior Year - GlobeNewswire Inc.
Immuron FY26 SalesFour Consecutive Quarters of Growth over Prior Year - Barchart.com
AVANTEL.NS Mar 2026 Earnings: EPS of ₹0.27 on Revenue of ₹63.15 CroreOne-Time Loss Impact - vinanet.vn
Immuron (NASDAQ: IMRN) advances IMM-529 CDI drug with new partnering push - Stock Titan
4.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):